论文部分内容阅读
目的观察血必净联合乌司他丁治疗感染性休克的临床疗效。方法 136例感染性休克患者,随机分成对照组及实验组,各68例。对照组患者进行常规治疗,实验组患者在常规治疗的基础上接受血必净与乌司他丁联合治疗。观察两组患者治疗前后PICCO监测指标的变化以及白细胞介素-6(IL-6)、降钙素原(PCT)、B型尿钠肽(BNP)的含量变化,同时观察两组患者的病情变化。结果治疗后实验组各项PICCO监测指标、IL-6、PCT、BNP水平均明显优于对照组(P<0.05);实验组患者治疗总有效率为89.7%,高于对照组患者的76.5%,差异具有统计学意义(P<0.05)。结论血必净并乌司他丁联合可以有效的治疗感染性休克,值得在今后的感染性休克治疗中继续推广使用。
Objective To observe the clinical efficacy of Xuebijing combined with ulinastatin in the treatment of septic shock. Methods 136 cases of septic shock were randomly divided into control group and experimental group, 68 cases in each. Patients in the control group were treated routinely. Patients in the experimental group received combined treatment with Xuebijing and ulinastatin on the basis of routine treatment. The changes of PICCO and the changes of IL-6, PCT and BNP in two groups before and after treatment were observed. At the same time, the changes of PICCO Variety. Results After treatment, all PICCO monitoring indicators, IL-6, PCT and BNP levels in the experimental group were significantly better than those in the control group (P <0.05). The total effective rate of the experimental group was 89.7%, which was higher than that of the control group (76.5% , The difference was statistically significant (P <0.05). Conclusions Xuebijing combined with ulinastatin can effectively treat septic shock and is worth further promotion in the treatment of septic shock in the future.